Boundless Bio to Participate in the Leerink Global Healthcare Conference

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focused on extrachromosomal DNA (ecDNA) biology research for treating oncogene amplified cancers, has announced its participation in the upcoming Leerink Global Healthcare Conference.

The company's President and CEO, Zachary Hornby, will engage in a fireside chat session scheduled for March 12, 2025, at 11:20 a.m. ET in Miami, FL. Investors and interested parties can access both live and archived webcasts of the presentation through the company's website under the Events & Presentations section in the Investors area.

02/26/2025 - 07:00 AM

SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, will participate in Leerink’s Global Healthcare Conference.

A fireside chat session is scheduled for Wednesday, March 12, 2025, in Miami, FL, at 11:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website and can be accessed via this link: https://wsw.com/webcast/leerink38/bold/2199477.

About Boundless Bio
Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in 14 to 17% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapeutic candidate (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Leveraging its Spyglass platform, Boundless Bio has additional programs advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA. For more information, visit www.boundlessbio.com and follow us on LinkedIn and X.

Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com

Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com

FAQ

When is Boundless Bio (BOLD) presenting at the Leerink Global Healthcare Conference 2025?

Boundless Bio will present on March 12, 2025, at 11:20 a.m. ET in Miami, FL.

How can investors watch Boundless Bio's (BOLD) Leerink Conference presentation?

Investors can access the live and archived webcast through Boundless Bio's website under Events & Presentations in the Investors section.

What type of cancer treatments is Boundless Bio (BOLD) developing?

Boundless Bio is developing transformative therapies for previously intractable oncogene amplified cancers by studying extrachromosomal DNA (ecDNA) biology.